Overall rank by patents
#42,629
of 49,997 tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G10K (Sound-producing DEVICES; Methods OR Devices FOR Protecting Against, OR FOR Damping, Noise OR Other Acoustic Waves IN GENERAL; Acoustics NOT Otherwise Provided FOR).
The verdict
According to USPTO PatentsView, Renesas ranks #42,629 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.
USPTO PatentsView assignee plate
Corpus R42629 · Foreign Corporation #42,629 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Relmada Therapeutics, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Renesas Design… · this assignee
40 score
3D Lighting… · lowest
7 score
What this shows Renesas's Innovation Score is 40.1/100 (top 36% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Renesas Design Netherlands B.V. is a focused PatentsView assignee: 7 CPC subclasses with 50% of grants classified under G10K (Sound-producing DEVICES; Methods OR Devices FOR Protecting Against, OR FOR Damping, Noise OR Other Acoustic Waves IN GENERAL; Acoustics NOT Otherwise Provided FOR). By volume, Renesas sits between Relmada Therapeutics, Inc. and Resonado, Inc..
Renesas Design Netherlands B.V. shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Relmada Therapeutics, Inc.
6 patents
Relola, Inc.
6 patents
Remcon Plastics Incorporated
6 patents
Renalsense Ltd.
6 patents
Renesas Semiconductor Package & Test Solutions Co., Ltd.
6 patents
RenovaCare Sciences Corp.
6 patents
Resolute Patents, LLC
6 patents
Resonado, Inc.
6 patents
Renesas Design Netherlands B.V.
6 patents
What this shows Renesas holds 6 patents at rank #42,658, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #42,658 in granted patent volume.
Other assignees with the most granted patents in Renesas's primary technology class.
Renesas's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
40 Top 36% higher than 64% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2024 | 2 | 33.3% |
| 2025partial year | 4 | 66.7% |
Top 7 of 7 technology areas
Overall rank by patents
#42,629
of 49,997 tracked assignees
40.1 out of 100
What to do with this data
Renesas Design Netherlands B.V.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.